Bristol Myers wins 'milestone' FDA approval of myeloma drug acquired from Celgene

Bristol Myers has received FDA approval for Zenbexus, a myeloma drug acquired from Celgene, marking the first clearance of the protein-degrading CELMoD medicine class and potentially rejuvenating Bristol Myers' key drug franchise.

This Wire brief sits within Fusion42's coverage of Biotech. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.